Home › Companies › Assembly Biosciences, Inc. › 2025-2026
At Assembly Biosciences, Inc.'s shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 56 asset managers reported how they voted in their SEC Form N-PX filings, covering 414 separate fund positions. Their filings are grouped here into 13 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF OUR NAMED EXECUTIVE OFFICERS' COMPENSATION. — Assembly Biosciences, Inc.'s filing reports the proposal as approved, with 99.9% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Assembly Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 5, 2026.
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Assembly Biosciences, Inc.’s Form 8-K, filed June 5, 2026 (Item 5.07 on EDGAR). Page generated November 8, 2026.
Meeting of June 4, 2026: 13 items on Assembly Biosciences, Inc.’s Form 8-K, filed June 5, 2026: 4 approved · 9 without a stated outcome.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Proxy season: 2025-2026
Explore Assembly Biosciences, Inc. in the interactive database Compare manager voting policies
These tallies are Assembly Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 5, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Anthony E. Altig | 11,300,212 | 16,008 | 621 | -- | 1,069,023 | 99.8% | Not verified | — |
| Elect Director: Tomas Cihlar, Ph.D. | 11,300,997 | 15,204 | 640 | -- | 1,069,023 | 99.8% | Not verified | — |
| Elect Director: Gina Consylman | 11,311,916 | 4,222 | 703 | -- | 1,069,023 | 99.9% | Not verified | — |
| Elect Director: Robert D. Cook II | 11,301,190 | 15,185 | 466 | -- | 1,069,023 | 99.8% | Not verified | — |
| Elect Director: Sir Michael Houghton, Ph.D. | 11,312,521 | 3,933 | 387 | -- | 1,069,023 | 99.9% | Not verified | — |
| Elect Director: Lisa R. Johnson-Pratt, M.D. | 11,296,644 | 3,662 | 16,535 | -- | 1,069,023 | 99.9% | Not verified | — |
| Elect Director: Susan Mahony, Ph.D. | 11,311,952 | 4,185 | 704 | -- | 1,069,023 | 99.9% | Not verified | — |
| Elect Director: John G. McHutchison, A.O., M.D. | 11,274,020 | 15,738 | 27,083 | -- | 1,069,023 | 99.8% | Not verified | — |
| Elect Director: Jason A. Okazaki | 11,310,730 | 5,729 | 382 | -- | 1,069,023 | 99.9% | Not verified | — |
| 2. On a non-binding advisory basis, the Company's named executive officers' compensation disclosed in the Proxy Statement | 11,293,061 | 5,401 | 18,379 | -- | 1,069,023 | 99.9% | Approved | — |
| 3. The selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 | 12,382,746 | 2,943 | 175 | -- | -- | 99.9% | Approved | — |
| 4. Amendment No | 11,290,805 | 24,242 | 1,794 | -- | 1,069,023 | 99.7% | Approved | — |
| 5. The ESPP Amendment No | 11,305,253 | 9,343 | 2,245 | -- | 1,069,023 | 99.9% | Approved | — |
Source: Assembly Biosciences, Inc., Form 8-K, filed with the SEC on June 5, 2026 — read the filing on EDGAR.
Each item below shows how the 56 asset managers that disclosed a Assembly Biosciences, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Assembly Biosciences, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 3 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Anthony E. Altig
Assembly Biosciences, Inc.’s own tally for this item (“Elect Director: Anthony E. Altig”): 11,300,212 for, 16,008 against, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 569,501 for, 938 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 477,195 | 880 | 0 | 0 | For |
| Fidelity | 49,939 | 0 | 0 | 0 | For |
| BlackRock | 13,897 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 7,195 | 0 | 0 | 0 | For |
| Charles Schwab | 6,704 | 0 | 0 | 0 | For |
| Invesco | 4,032 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,341 | 0 | 0 | 0 | For |
| Northern Trust | 2,612 | 0 | 0 | 0 | For |
| American Century | 2,236 | 0 | 0 | 0 | For |
| Equitable | 1,665 | 0 | 0 | 0 | For |
| Federated Hermes | 289 | 0 | 0 | 0 | For |
| John Hancock | 281 | 0 | 0 | 0 | For |
| Victory Capital | 115 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 58 | 0 | 0 | Against |
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Gina Consylman
Assembly Biosciences, Inc.’s own tally for this item (“Elect Director: Gina Consylman”): 11,311,916 for, 4,222 against, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 569,501 for, 938 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 477,195 | 880 | 0 | 0 | For |
| Fidelity | 49,939 | 0 | 0 | 0 | For |
| BlackRock | 13,897 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 7,195 | 0 | 0 | 0 | For |
| Charles Schwab | 6,704 | 0 | 0 | 0 | For |
| Invesco | 4,032 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,341 | 0 | 0 | 0 | For |
| Northern Trust | 2,612 | 0 | 0 | 0 | For |
| American Century | 2,236 | 0 | 0 | 0 | For |
| Equitable | 1,665 | 0 | 0 | 0 | For |
| Federated Hermes | 289 | 0 | 0 | 0 | For |
| John Hancock | 281 | 0 | 0 | 0 | For |
| Victory Capital | 115 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 58 | 0 | 0 | Against |
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Jason A. Okazaki
Assembly Biosciences, Inc.’s own tally for this item (“Elect Director: Jason A. Okazaki”): 11,310,730 for, 5,729 against, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 570,440 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 478,076 | 0 | 0 | 0 | For |
| Fidelity | 49,939 | 0 | 0 | 0 | For |
| BlackRock | 13,897 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 7,195 | 0 | 0 | 0 | For |
| Charles Schwab | 6,704 | 0 | 0 | 0 | For |
| Invesco | 4,032 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,341 | 0 | 0 | 0 | For |
| Northern Trust | 2,612 | 0 | 0 | 0 | For |
| American Century | 2,236 | 0 | 0 | 0 | For |
| Equitable | 1,665 | 0 | 0 | 0 | For |
| Federated Hermes | 289 | 0 | 0 | 0 | For |
| John Hancock | 281 | 0 | 0 | 0 | For |
| Victory Capital | 115 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 58 | 0 | 0 | 0 | For |
Combines 4 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: John G. McHutchison, A.O., M.D.
Assembly Biosciences, Inc.’s own tally for this item (“Elect Director: John G. McHutchison, A.O., M.D.”): 11,274,020 for, 15,738 against, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 569,501 for, 938 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 477,195 | 880 | 0 | 0 | For |
| Fidelity | 49,939 | 0 | 0 | 0 | For |
| BlackRock | 13,897 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 7,195 | 0 | 0 | 0 | For |
| Charles Schwab | 6,704 | 0 | 0 | 0 | For |
| Invesco | 4,032 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,341 | 0 | 0 | 0 | For |
| Northern Trust | 2,612 | 0 | 0 | 0 | For |
| American Century | 2,236 | 0 | 0 | 0 | For |
| Equitable | 1,665 | 0 | 0 | 0 | For |
| Federated Hermes | 289 | 0 | 0 | 0 | For |
| John Hancock | 281 | 0 | 0 | 0 | For |
| Victory Capital | 115 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 58 | 0 | 0 | Against |
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Lisa R. Johnson-Pratt, M.D.
Assembly Biosciences, Inc.’s own tally for this item (“Elect Director: Lisa R. Johnson-Pratt, M.D.”): 11,296,644 for, 3,662 against, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 569,501 for, 938 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 477,195 | 880 | 0 | 0 | For |
| Fidelity | 49,939 | 0 | 0 | 0 | For |
| BlackRock | 13,897 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 7,195 | 0 | 0 | 0 | For |
| Charles Schwab | 6,704 | 0 | 0 | 0 | For |
| Invesco | 4,032 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,341 | 0 | 0 | 0 | For |
| Northern Trust | 2,612 | 0 | 0 | 0 | For |
| American Century | 2,236 | 0 | 0 | 0 | For |
| Equitable | 1,665 | 0 | 0 | 0 | For |
| Federated Hermes | 289 | 0 | 0 | 0 | For |
| John Hancock | 281 | 0 | 0 | 0 | For |
| Victory Capital | 115 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 58 | 0 | 0 | Against |
Combines 3 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Robert D. Cook II
Assembly Biosciences, Inc.’s own tally for this item (“Elect Director: Robert D. Cook II”): 11,301,190 for, 15,185 against, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 570,440 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 478,076 | 0 | 0 | 0 | For |
| Fidelity | 49,939 | 0 | 0 | 0 | For |
| BlackRock | 13,897 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 7,195 | 0 | 0 | 0 | For |
| Charles Schwab | 6,704 | 0 | 0 | 0 | For |
| Invesco | 4,032 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,341 | 0 | 0 | 0 | For |
| Northern Trust | 2,612 | 0 | 0 | 0 | For |
| American Century | 2,236 | 0 | 0 | 0 | For |
| Equitable | 1,665 | 0 | 0 | 0 | For |
| Federated Hermes | 289 | 0 | 0 | 0 | For |
| John Hancock | 281 | 0 | 0 | 0 | For |
| Victory Capital | 115 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 58 | 0 | 0 | 0 | For |
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Sir Michael Houghton, Ph.D.
Assembly Biosciences, Inc.’s own tally for this item (“Elect Director: Sir Michael Houghton, Ph.D.”): 11,312,521 for, 3,933 against, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 569,501 for, 938 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 477,195 | 880 | 0 | 0 | For |
| Fidelity | 49,939 | 0 | 0 | 0 | For |
| BlackRock | 13,897 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 7,195 | 0 | 0 | 0 | For |
| Charles Schwab | 6,704 | 0 | 0 | 0 | For |
| Invesco | 4,032 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,341 | 0 | 0 | 0 | For |
| Northern Trust | 2,612 | 0 | 0 | 0 | For |
| American Century | 2,236 | 0 | 0 | 0 | For |
| Equitable | 1,665 | 0 | 0 | 0 | For |
| Federated Hermes | 289 | 0 | 0 | 0 | For |
| John Hancock | 281 | 0 | 0 | 0 | For |
| Victory Capital | 115 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 58 | 0 | 0 | Against |
Combines 3 wordings of this item as funds reported it.
99.9% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Susan Mahony, Ph.D.
Assembly Biosciences, Inc.’s own tally for this item (“Elect Director: Susan Mahony, Ph.D.”): 11,311,952 for, 4,185 against, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 569,501 for, 938 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 477,195 | 880 | 0 | 0 | For |
| Fidelity | 49,939 | 0 | 0 | 0 | For |
| BlackRock | 13,897 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 7,195 | 0 | 0 | 0 | For |
| Charles Schwab | 6,704 | 0 | 0 | 0 | For |
| Invesco | 4,032 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,341 | 0 | 0 | 0 | For |
| Northern Trust | 2,612 | 0 | 0 | 0 | For |
| American Century | 2,236 | 0 | 0 | 0 | For |
| Equitable | 1,665 | 0 | 0 | 0 | For |
| Federated Hermes | 289 | 0 | 0 | 0 | For |
| John Hancock | 281 | 0 | 0 | 0 | For |
| Victory Capital | 115 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 0 | 58 | 0 | 0 | Against |
Combines 3 wordings of this item as funds reported it.
99.8% Majority: yes · of votes cast
Description as filed by funds: Election of Directors: Tomas Cihlar, Ph.D.
Assembly Biosciences, Inc.’s own tally for this item (“Elect Director: Tomas Cihlar, Ph.D.”): 11,300,997 for, 15,204 against, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 570,440 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 478,076 | 0 | 0 | 0 | For |
| Fidelity | 49,939 | 0 | 0 | 0 | For |
| BlackRock | 13,897 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 7,195 | 0 | 0 | 0 | For |
| Charles Schwab | 6,704 | 0 | 0 | 0 | For |
| Invesco | 4,032 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,341 | 0 | 0 | 0 | For |
| Northern Trust | 2,612 | 0 | 0 | 0 | For |
| American Century | 2,236 | 0 | 0 | 0 | For |
| Equitable | 1,665 | 0 | 0 | 0 | For |
| Federated Hermes | 289 | 0 | 0 | 0 | For |
| John Hancock | 281 | 0 | 0 | 0 | For |
| Victory Capital | 115 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 58 | 0 | 0 | 0 | For |
99.5% of fund votes cast · no official result
Description as filed by funds: APPROVAL OF AN AMENDMENT TO OUR AMENDED AND RESTATED 2018 STOCK INCENTIVE PLAN TO INCREASE THE NUMBER OF SHARES RESERVED FOR ISSUANCE THEREUNDER BY 1,200,000 SHARES.
The 14 asset managers below reported 567,915 for, 2,525 against. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 478,076 | 0 | 0 | 0 | For |
| Fidelity | 49,939 | 0 | 0 | 0 | For |
| BlackRock | 13,897 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 7,195 | 0 | 0 | 0 | For |
| Charles Schwab | 6,704 | 0 | 0 | 0 | For |
| Invesco | 4,032 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,341 | 0 | 0 | 0 | For |
| Northern Trust | 2,612 | 0 | 0 | 0 | For |
| American Century | 0 | 2,236 | 0 | 0 | Against |
| Equitable | 1,665 | 0 | 0 | 0 | For |
| Federated Hermes | 0 | 289 | 0 | 0 | Against |
| John Hancock | 281 | 0 | 0 | 0 | For |
| Victory Capital | 115 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 58 | 0 | 0 | 0 | For |
100% of fund votes cast · no official result
Description as filed by funds: APPROVAL OF AN AMENDMENT TO OUR SECOND AMENDED AND RESTATED 2018 EMPLOYEE STOCK PURCHASE PLAN TO INCREASE THE AUTHORIZED NUMBER OF SHARES RESERVED FOR ISSUANCE THEREUNDER TO 515,000 SHARES.
The 14 asset managers below reported 570,440 for. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 478,076 | 0 | 0 | 0 | For |
| Fidelity | 49,939 | 0 | 0 | 0 | For |
| BlackRock | 13,897 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 7,195 | 0 | 0 | 0 | For |
| Charles Schwab | 6,704 | 0 | 0 | 0 | For |
| Invesco | 4,032 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,341 | 0 | 0 | 0 | For |
| Northern Trust | 2,612 | 0 | 0 | 0 | For |
| American Century | 2,236 | 0 | 0 | 0 | For |
| Equitable | 1,665 | 0 | 0 | 0 | For |
| Federated Hermes | 289 | 0 | 0 | 0 | For |
| John Hancock | 281 | 0 | 0 | 0 | For |
| Victory Capital | 115 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 58 | 0 | 0 | 0 | For |
Combines 5 wordings of this item as funds reported it.
99.9% Approved · of votes cast
Description as filed by funds: APPROVAL, ON A NON-BINDING ADVISORY BASIS, OF OUR NAMED EXECUTIVE OFFICERS' COMPENSATION.
Assembly Biosciences, Inc.’s own tally for this item (“2. On a non-binding advisory basis, the Company's named executive officers' compensation disclosed in the Proxy Statement”): 11,293,061 for, 5,401 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders approved, on a non-binding advisory basis, the Company's named executive officers' compensation disclosed in the Proxy Statement.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 478,076 | 0 | 0 | 0 | For |
| Fidelity | 49,939 | 0 | 0 | 0 | For |
| BlackRock | 13,897 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 7,195 | 0 | 0 | 0 | For |
| Charles Schwab | 6,704 | 0 | 0 | 0 | For |
| Invesco | 4,032 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,341 | 0 | 0 | 0 | For |
| Northern Trust | 2,612 | 0 | 0 | 0 | For |
| American Century | 2,236 | 0 | 0 | 0 | For |
| Equitable | 1,665 | 0 | 0 | 0 | For |
| Federated Hermes | 289 | 0 | 0 | 0 | For |
| John Hancock | 281 | 0 | 0 | 0 | For |
| Victory Capital | 115 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 58 | 0 | 0 | 0 | For |
Fund voting reports, all 14 managers: 570,440 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 4,505,391 | 0 | 0 | 0 | For |
| FARALLON CAPITAL MANAGEMENT, L.L.C. | 1,227,590 | 0 | 0 | 0 | For |
| RA CAPITAL MANAGEMENT, L.P. | 1,020,410 | 0 | 0 | 0 | For |
| Commodore Capital LP | 1,000,000 | 0 | 0 | 0 | For |
| Paradigm Biocapital Advisors LP | 640,452 | 0 | 0 | 0 | For |
| Janus Henderson | 603,024 | 0 | 0 | 0 | For |
| Blackstone Inc. | 174,618 | 0 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 161,000 | 0 | 0 | 0 | For |
| B Group, Inc. | 150,162 | 0 | 0 | 0 | For |
| BlackRock | 109,769 | 0 | 0 | 0 | For |
| Vanguard | 75,777 | 0 | 0 | 0 | For |
| Point72 | 75,565 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 75,462 | 0 | 0 | 0 | For |
| HighVista Strategies LLC | 74,735 | 0 | 0 | 0 | For |
| MARSHALL WACE, LLP | 73,942 | 0 | 0 | 0 | For |
| Eversept Partners, LP | 40,889 | 0 | 0 | 0 | For |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 37,938 | 0 | 0 | 0 | For |
| 683 Capital Management, LLC | 27,863 | 0 | 0 | 0 | For |
| Citadel | 25,072 | 0 | 0 | 0 | For |
| Wellington | 18,524 | 0 | 0 | 0 | For |
| Two Sigma | 16,027 | 0 | 0 | 0 | For |
| MONIMUS CAPITAL MANAGEMENT, LP | 0 | 0 | 15,833 | 0 | Abstain |
| Northern Trust | 11,835 | 0 | 0 | 0 | For |
| Hudson Bay Capital Management LP | 10,728 | 0 | 0 | 0 | For |
| Connor, Clark & Lunn Investment Management Ltd. | 9,127 | 0 | 0 | 0 | For |
Institutional-manager reports, all 50 managers: 10,215,195 for, 627 against, 15,833 abstained. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Approved · of votes cast
Description as filed by funds: RATIFICATION OF THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.
Assembly Biosciences, Inc.’s own tally for this item (“3. The selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 12,382,746 for, 2,943 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “The stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 14 asset managers below reported 570,440 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 478,076 | 0 | 0 | 0 | For |
| Fidelity | 49,939 | 0 | 0 | 0 | For |
| BlackRock | 13,897 | 0 | 0 | 0 | For |
| ETFis Series Trust I | 7,195 | 0 | 0 | 0 | For |
| Charles Schwab | 6,704 | 0 | 0 | 0 | For |
| Invesco | 4,032 | 0 | 0 | 0 | For |
| Goldman Sachs | 3,341 | 0 | 0 | 0 | For |
| Northern Trust | 2,612 | 0 | 0 | 0 | For |
| American Century | 2,236 | 0 | 0 | 0 | For |
| Equitable | 1,665 | 0 | 0 | 0 | For |
| Federated Hermes | 289 | 0 | 0 | 0 | For |
| John Hancock | 281 | 0 | 0 | 0 | For |
| Victory Capital | 115 | 0 | 0 | 0 | For |
| Advisors' Inner Circle Fund III | 58 | 0 | 0 | 0 | For |
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 15,892,608 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 3.01% |
| 2 | Fidelity | 0.31% |
| 3 | BlackRock | 0.09% |
| 4 | ETFis Series Trust I | 0.05% |
| 5 | Charles Schwab | 0.04% |
| 6 | Invesco | 0.03% |
| 7 | Goldman Sachs | 0.02% |
| 8 | Northern Trust | 0.02% |
| 9 | American Century | 0.01% |
| 10 | Equitable | 0.01% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | GILEAD SCIENCES, INC. | 28.35% |
| 2 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 7.72% |
| 3 | RA CAPITAL MANAGEMENT, L.P. | 6.42% |
| 4 | Commodore Capital LP | 6.29% |
| 5 | Paradigm Biocapital Advisors LP | 4.03% |
| 6 | Janus Henderson | 3.79% |
| 7 | Blackstone Inc. | 1.10% |
| 8 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.01% |
| 9 | B Group, Inc. | 0.94% |
| 10 | BlackRock | 0.69% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| GILEAD SCIENCES, INC. | — | 13D |
| Entities affiliated with Commodore Capital L.P. | — | DEF14A |
| Farallon Capital Management, L.L.C. | — | 13G |
| Paradigm BioCapital Advisors LP | — | 13G |
| Entities affiliated with RA Capital Management L.P. | — | DEF14A |
| JANUS HENDERSON GROUP Ltd. | — | 13G |
| Entities affiliated with Janus Henderson Group plc | — | DEF14A |
| Entities affiliated with Farallon Capital Partners L.P. | — | DEF14A |
| Vanguard Group | — | 13F |
| Point72 | — | 13F |
Percentages above are of 15,892,608 shares outstanding, as reported by Assembly Biosciences, Inc. on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Assembly Biosciences, Inc.’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 8, 2026; a live search always shows the current data.
Assembly Biosciences, Inc. proxy season coverage: 2025-2026 (this page).
proxyvotesnow.com, “Assembly Biosciences (ASMB) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/assembly-biosciences-inc/2026 (version of November 9, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.